AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read

HC Wainwright & Co. reiterates Buy rating on Cullinan Therapeutics, $35 price target

HC Wainwright reiterated a Buy rating on Cullinan Therapeutics with a $35 price target, implying 140.9% upside from the Oct 1 close. The firm cited strong clinical data for zipalertinib, including a 65% overall response rate, and potential milestone payments of $100 million upon approval.

Original reporting
tradingview.com
Published Oct 2, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Cullinan Therapeutics, $35 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's target implies a 140% upside, likely prompting buying interest.

02

Market read

New clinical data and a raised price target provide a fresh catalyst for CLLN.

03

What to watch

Potential competition from other zipline inhibitors could limit market share.

Relevance 8/10Novelty 8/10Timing: today

Background

HC Wainwright analyst note reiterates a buy rating with a $35 target based on new zipalertinib data.

Market effects

Sector

Boosts sentiment for oncology biotech sector.

Regional

U.S. biotech investors may increase exposure.

Global

Limited to markets tracking biotech pipelines.

Counterpoint

What could challenge this read

Milestone payments are contingent on FDA approval, which remains uncertain.

Key entities

  • company
    Cullinan Therapeutics

    Biotech developing zipalertinib for cancer treatment.

  • research_firm
    HC Wainwright & Co.

    Equity research firm issuing the rating.

Read at source← All news

Related articles

OCT 2
$CGEMMedAI 8/10

Cullinan Therapeutics starts NDA submission for zipalertinib plus chemo under FDA RTOR

Cullinan Therapeutics began submitting an NDA to the FDA for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion NSCLC under the RTOR program. The submission is based on the Phase 3 REZILIENT3 trial, which met its primary endpoint. The company expects to complete the submission by year-end 2026. Zipalertinib has FDA Breakthrough Therapy designation, and a separate NDA for monotherapy has a PDUFA date of Feb 27, 2027.

tradingview.com1 min
OCT 2
$CGEMMedAI 9/10

Cullinan's Zipalertinib Combination Heads To FDA After Positive Phase 3 Lung Cancer Trial

Cullinan Therapeutics (CGEM) submitted a New Drug Application to the FDA for zipalertinib in combination with chemotherapy to treat a specific type of lung cancer. The submission is under the FDA's Real-Time Oncology Review program and is supported by positive Phase 3 trial data showing improved progression-free survival. The company expects to complete the submission by the end of 2026. CGEM's stock closed at $14.53, down 5.34%.

rttnews.com2 min
OCT 1
$CGEMHighAI 8/10

Cullinan initiates FDA filing for lung cancer drug zipalertinib

Cullinan Therapeutics (CGEM) initiated an FDA filing for zipalertinib, a lung cancer drug, in combination with chemotherapy. The Phase 3 trial met its primary endpoint, showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive $130 million in milestones upon approvals. Zipalertinib is being developed with Taiho Oncology and Taiho Pharmaceutical.

investing.com2 min
OCT 1
$CGEMMedAI 8/10

Cullinan Therapeutics, Inc. (CGEM): New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA…

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated long

SEC EDGAR 8-K2 min
OCT 1
$CGEMHighAI 8/10

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

Cullinan Therapeutics (CGEM) initiated NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon20ins NSCLC under FDA's RTOR program, with completion expected by year-end 2026. The submission follows positive Phase 3 REZILIENT3 trial results, showing significant improvement in progression-free survival. Zipalertinib has FDA Breakthrough Therapy designation, and Cullinan may receive $100M in milestone payments upon approval.

globenewswire.com2 min